JP2005506151A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506151A5
JP2005506151A5 JP2003537695A JP2003537695A JP2005506151A5 JP 2005506151 A5 JP2005506151 A5 JP 2005506151A5 JP 2003537695 A JP2003537695 A JP 2003537695A JP 2003537695 A JP2003537695 A JP 2003537695A JP 2005506151 A5 JP2005506151 A5 JP 2005506151A5
Authority
JP
Japan
Prior art keywords
stent
formula
group
compound
thrombosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003537695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506151A (ja
Filing date
Publication date
Priority claimed from DE10152460A external-priority patent/DE10152460A1/de
Application filed filed Critical
Publication of JP2005506151A publication Critical patent/JP2005506151A/ja
Publication of JP2005506151A5 publication Critical patent/JP2005506151A5/ja
Pending legal-status Critical Current

Links

JP2003537695A 2001-10-24 2002-10-11 ステント Pending JP2005506151A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152460A DE10152460A1 (de) 2001-10-24 2001-10-24 Stents
PCT/EP2002/011402 WO2003035133A1 (de) 2001-10-24 2002-10-11 Stents

Publications (2)

Publication Number Publication Date
JP2005506151A JP2005506151A (ja) 2005-03-03
JP2005506151A5 true JP2005506151A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=7703557

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003537695A Pending JP2005506151A (ja) 2001-10-24 2002-10-11 ステント

Country Status (22)

Country Link
US (1) US20050064006A1 (cg-RX-API-DMAC7.html)
EP (1) EP1439869A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506151A (cg-RX-API-DMAC7.html)
KR (1) KR20040074977A (cg-RX-API-DMAC7.html)
CN (1) CN1575189A (cg-RX-API-DMAC7.html)
AU (1) AU2002340549B2 (cg-RX-API-DMAC7.html)
BR (1) BR0213481A (cg-RX-API-DMAC7.html)
CA (1) CA2464290A1 (cg-RX-API-DMAC7.html)
DE (1) DE10152460A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP045075A (cg-RX-API-DMAC7.html)
EE (1) EE200400080A (cg-RX-API-DMAC7.html)
HR (1) HRP20040456A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0401760A3 (cg-RX-API-DMAC7.html)
IL (1) IL161445A0 (cg-RX-API-DMAC7.html)
MA (1) MA26341A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003755A (cg-RX-API-DMAC7.html)
NO (1) NO20041984L (cg-RX-API-DMAC7.html)
NZ (1) NZ532443A (cg-RX-API-DMAC7.html)
PL (1) PL367968A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004115757A (cg-RX-API-DMAC7.html)
WO (1) WO2003035133A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200402989B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
WO2007039132A1 (de) 2005-10-04 2007-04-12 Bayer Healthcare Ag Neue polymorphe form und die amorphe form von 5-chlor-n- ( { ( 5s ) -2-0x0-3-[4-( 3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2- thiophencarboxamid
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
US20070097252A1 (en) * 2005-10-31 2007-05-03 Silverstein D A Imaging methods, cameras, projectors, and articles of manufacture
DE102006034916A1 (de) * 2006-07-28 2008-01-31 Bayer Healthcare Ag Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2009063028A2 (en) * 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
WO2021242783A1 (en) * 2020-05-26 2021-12-02 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181735T1 (de) * 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
US6133256A (en) * 1997-04-14 2000-10-17 Cor Therapeutics Inc Selective factor Xa inhibitors
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US20010029351A1 (en) * 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung

Similar Documents

Publication Publication Date Title
RU2004101404A (ru) Комбинированная терапия с помощью замещенных оксазолидинов
CN100540538C (zh) 高传导率钙-活化k通道开启剂
RU2006122599A (ru) Способ изготовления твердого, орально применяемого фармацевтического состава
JP2006528986A5 (cg-RX-API-DMAC7.html)
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
RU2008116828A (ru) Комбинированный метод терапии замещенными оксазолидинонами для профилактики и лечения нарушений церебрального местного кровообращения
JP2008503484A5 (cg-RX-API-DMAC7.html)
RU2004115757A (ru) Стенты
JP2007512299A5 (cg-RX-API-DMAC7.html)
CA2522435A1 (en) Inhibitors of akt activity
JP2004528334A5 (cg-RX-API-DMAC7.html)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2004506632A5 (cg-RX-API-DMAC7.html)
HUP9801883A2 (hu) Farnezil-protein transzferáz enzim gátló piperazinszármazékok, előállításuk, alkalmazásuk, és a vegyületeket tartalmazó gyógyszerkészítmények
JP2005517006A5 (cg-RX-API-DMAC7.html)
CA2668068A1 (en) Combination therapy of substituted oxazolidinones
JP2004536869A5 (cg-RX-API-DMAC7.html)
JP2020533352A5 (cg-RX-API-DMAC7.html)
JP2019518770A5 (cg-RX-API-DMAC7.html)
AR035603A1 (es) Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2009062388A5 (cg-RX-API-DMAC7.html)
JP2005519885A5 (cg-RX-API-DMAC7.html)
CA2596145A1 (en) Prevention and treatment of thromboembolic disorders
JP2020534266A5 (cg-RX-API-DMAC7.html)